Daiichi Sankyo And Merck: Ifinatamab Deruxtecan Shows Promising Results In Phase 2 ES-SCLC Trial
Daiichi Sankyo And Merck: Ifinatamab Deruxtecan Shows Promising Results In Phase 2 ES-SCLC Trial
2 months ago
finanznachrichten.de
Daiichi Sankyo And Merck Receive Priority Review For Ifinatamab Deruxtecan In Previously Treated Extensive-Stage Small Cell Lung Cancer
Daiichi Sankyo And Merck Receive Priority Review For Ifinatamab Deruxtecan In Previously Treated Extensive-Stage Small Cell Lung Cancer
1 month ago
marketscreener.com
Dr Johnson on the Initial Efficacy of Ifinatamab Deruxtecan in Refractory SCLC | OncLive
Dr Johnson on the Initial Efficacy of Ifinatamab Deruxtecan in Refractory SCLC | OncLive
Sep 18, 2023
onclive.com
ADC momentum in SCLC from @RManochakian at ILCS 2025. B7 H3 ADC ifinatamab deruxtecan and DLL3 ADC SHR4849 report response rates beyond 50% and OS near ten months in heavily pretreated patients. Toxicity and biomarkers now move center stage.Full talk here ➡️
2:22
ADC momentum in SCLC from @RManochakian at ILCS 2025. B7 H3 ADC ifinatamab deruxtecan and DLL3 ADC SHR4849 report response rates beyond 50% and OS near ten months in heavily pretreated patients. Toxicity and biomarkers now move center stage.Full talk here ➡️
1.7K views1 month ago
x.comInternational Lung Cancer Summit
Trending in Oncology: Ifinatamab Priority Review and more
2:54
Trending in Oncology: Ifinatamab Priority Review and more
3 weeks ago
YouTubeLucidQuest
Intracranial Efficacy of Datopotamab Deruxtecan in Patients With Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From TROPION-Lung05 | OncLive
9:52
Intracranial Efficacy of Datopotamab Deruxtecan in Patients With Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From TROPION-Lung05 | OncLive
Jun 27, 2024
onclive.com
Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01 | OncLive
Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01 | OncLive
Nov 5, 2024
onclive.com
2:57
Oncology Update – 27 Apr 2026: Ifinatamab Priority Review, Ojemda EU Approval and More
9 views3 weeks ago
YouTubeLucidQuest
Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Nov 11, 2024
marketscreener.com
11:55
Datopotamab Deruxtecan (Dato-DXd) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) – Nonsquamous (NSQ) Histology in the Phase 3 TROPION-Lung01 Trial | OncLive
Apr 9, 2024
onclive.com
Recognizing and Treating Interstitial Lung Disease Associated With Trastuzumab Deruxtecan | OncLive
11 months ago
onclive.com
3:58
Datopotamab Deruxtecan: A New ADC Option for EGFR-Mutated NSCLC | Pharmacy Times
4 months ago
pharmacytimes.com
FDA Approves First Targeted Drug To Treat HER2-Low Breast Cancer: Trastuzumab Deruxtecan (T-DXd)
Aug 5, 2022
mskcc.org
Trastuzumab Deruxtecan in the Curative Setting: Neoadjuvant and Adjuvant Advances | OncLive
3 months ago
onclive.com
11:11
Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy for Patients with Metastatic HR /HER2– BC: Primary Results from the Randomized Phase III TROPION-Breast01 Trial | OncLive
Oct 30, 2023
onclive.com
6:32
The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR , HER2- Breast Cancer | OncLive
Feb 16, 2024
onclive.com
LBA1 - Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2 ) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05 | OncLive
6 months ago
onclive.com
3:56
How Do ADCs Work? New hope in Cancer Treatment: Patritumab Deruxtecan, Ifentimab Deruxtecan
296 viewsOct 25, 2023
YouTubeDr. Constantin
18:35
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer
141 views8 months ago
YouTubeDecera Clinical Education
0:09
IDeate-Esophageal01 Phase 3 Trial: Ifinatamab Deruxtecan in Esophageal Squamous Cell Carcinoma
235 viewsMay 20, 2025
YouTubeMCQ Pedia
1:25
Dato-DXd: a new ADC on the block
1.5K viewsMay 17, 2021
YouTubeVJOncology
2:02
Dr Sands on the Evolving Role of ADCs in SCLC Management
157 viewsJul 26, 2024
YouTubeOncLive
9:47
Targeting TROP2: Datopotamab Deruxtecan (Dato-DXd) - Lung Cancer OncInsights 2025-26
170 views5 months ago
YouTubeGlobal Resource for Advancing Cancer Education
6:52
Treating HER-2 Mutated Lung Cancer: Trastuzumab Deruxtecan - Lung Cancer OncInsights 2025-26
75 views5 months ago
YouTubeGlobal Resource for Advancing Cancer Education
0:22
How Datopotamab Deruxtecan Attacks Only Cancer Cells #CancerTreatment #MedicalExplained
744 views11 months ago
YouTubeRx Explained
3:18
Antibody-Drug Conjugates in Small Cell Lung Cancer - 2024 Lung Cancer OncTalk
134 viewsJan 21, 2025
YouTubeGlobal Resource for Advancing Cancer Education
GO2 for Lung Cancer on Instagram: "🚨 @FDA approval news: Datroway (datopotamab deruxtecan-dlnk) has received accelerated approval for EGFR-positive non-small cell lung cancer (NSCLC). This new option is for people who have already been treated with EGFR-targeted therapy and chemotherapy—offering fresh hope when other treatments may have stopped working. 🔗 LINK IN BIO to learn more about how it works and what this means for the lung cancer community. #LungCancer #LungCancerTreatment #TargetedTr
5.2K views10 months ago
Instagramgo2forlungcancer
22:23
FDA Approval of Datopotamab deruxtecan (Dato-DXd) in EGFR Mutated Lung Cancer - Dr. Jacob Sands
4.7K views9 months ago
YouTubeOncBrothers: Practice-Changing Cancer Discu…
1:54
Datopotamab Deruxtecan in NSCLC: A Closer Look at TROP2-Targeted Therapy
924 views10 months ago
YouTubeOncUpdates: Latest Oncology Insights
1:10
Oncologists Discuss Future of Trastuzumab Deruxtecan in Curative Setting
111 views3 months ago
YouTubeThe Oncology Brief
See more
Static thumbnail place holder